<DOC>
	<DOCNO>NCT02320084</DOCNO>
	<brief_summary>The purpose study look long term safety profile Orfadin treatment patient suffer hereditary tyrosinemia type 1 ( HT-1 ) . Patients include study use Orfadin accord normal clinical practice .</brief_summary>
	<brief_title>Long Term Safety Study Orfadin Treatment HT-1 Patients Standard Clinical Care</brief_title>
	<detailed_description>The plan study non-interventional study look long-term safety Orfadin treatment patient suffer hereditary tyrosinemia type 1 . Orfadin use accord normal practice . There ongoing post-marketing surveillance ( PMS ) program monitor hepatic , renal , hematological , neurological ophthalmic status patient treat Orfadin . The Committee medicinal Products Human Use ( CHMP ) require program look data approximately 400 patient find benefit-risk ratio positive . The present study ( PASS ) replace ongoing PMS . The transition country gradual ; start 2013.The study include HT-1 patient Orfadin treatment standard clinical care well newly diagnose patient start Orfadin treatment .</detailed_description>
	<mesh_term>Tyrosinemias</mesh_term>
	<mesh_term>Nitisinone</mesh_term>
	<criteria>All HT1 patient receive Orfadin treatment eligible entry . No exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HT-1</keyword>
	<keyword>Hereditary Tyrosinemia , Type I</keyword>
	<keyword>hypertyrosinemia type 1</keyword>
	<keyword>Orfadin</keyword>
	<keyword>Long term safety</keyword>
	<keyword>Hereditary Tyrosinemia Type 1</keyword>
</DOC>